Craig A. Wheeler
President and Chief Executive Officer
Jim Anderson, Ph.D.
Senior Vice President, Pharmaceutical Science
Santiago Arroyo, M.D., Ph.D.
Senior Vice President, Development and Chief Medical Officer
Senior Vice President, Human Resources
Ian D. Fier
Senior Vice President, Program and Alliance Leadership
Ganesh V. Kaundinya, Ph.D.
Chief Operating Officer, Chief Scientific Officer and Co-Founder
Young Kwon, Ph.D.
Senior Vice President, Corporate Development and Strategy
Bruce A. Leicher
Senior Vice President, General Counsel and Secretary
Anthony Manning, Ph.D.
Senior Vice President, Research
Scott M. Storer
Senior Vice President, Chief Financial Officer and Treasurer
Mr. Wheeler joined Momenta as CEO in September of 2006. He led the company through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. He has overseen the company’s growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron BioPharmaceuticals where during his five-year tenure the pharmaceutical division’s global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector. He began his career at Merck’s MSDRL research unit. Mr. Wheeler is currently a member of the Board of Directors of Amicus Therapeutics as well as the Association for Accessible Medicines (AAM) where he previously served as Chairman from 2014 to February 2016. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion.
Dr. Anderson joined Momenta Pharmaceuticals in March of 2007. He is responsible for the establishment of manufacturing processes and associated controls, supply of clinical materials, transfer of commercial processes to external CMO partners, and preparation of CMC regulatory submissions for all of Momenta’s products that are in development. Dr. Anderson initially joined Momenta as the head of the Analytical Development organization. Prior to Momenta, he was the Director of Pharmacy and Analytical Development at Bristol-Myers Squibb Medical Imaging, where he led project teams for new drug product programs. In total, Dr. Anderson has approximately 25 years of CMC development experience.
Dr. Arroyo joined Momenta in June of 2017. He is responsible for preclinical and clinical development and regulatory affairs. He joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer. Previously he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Cardiovascular and Metabolism, Pain, Neuroscience, Regenerative Medicine and Rare Diseases. He was previously Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and at the Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.
Ms. Beltramello joined Momenta in October of 2007. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.
Mr. Fier joined Momenta in October of 2002. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA in Heath Care Management from Boston University.
Dr. Kaundinya is one of Momenta's founders. Since inception, Dr. Kaundinya has played a key role in defining the business and scientific strategy and in building and leading the research organization. Prior to founding Momenta, Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology. He is a Member of Scientific Advisory Board at Siamab Therapeutics, Inc. (formerly Sialix, Inc.) and has also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-million dollar NIH initiative to study the role of complex sugars in biology, and was a Research Faculty Member of the Harvard of M.I.T. division of Health and Sciences and Technology, where he investigated the biochemistry and biophysics of carbohydrates and research in the area of analytical techniques for complex carbohydrates. Dr. Kaundinya received both his M.S. and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.
Dr. Kwon joined Momenta in January of 2011. At Momenta, he is responsible for driving business and corporate development strategy aimed at achieving Momenta’s corporate objectives. These objectives include further developing our biosimilars and novel drug businesses through strategic transactions like those with Baxter Healthcare, Virdante Pharmaceuticals and others. He was previously Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. He has co-authored numerous peer-reviewed publications in the area of neurobiology.
Mr. Leicher joined Momenta in July of 2008. He was previously Senior Vice President and General Counsel at Altus Pharmaceuticals Inc. and also served as General Counsel and in senior legal positions at Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc., and Wyeth. Mr. Leicher brings significant legal expertise in research and product development, product commercialization and launch, corporate finance and partnering transactions, intellectual property law and licensing, corporate governance and litigation. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow and was an attorney at Hale and Dorr and Butler and Binion.
Mr. Storer joined Momenta in November 2016 as Senior Vice President and Chief Financial Officer. At Momenta, he is responsible for Finance, Accounting, Investor Relations, Information Technology and Facilities. Prior to joining Momenta, Mr. Storer was Senior Vice President, Finance at Baxalta, Inc. following its spin-out from Baxter International in July 2015. Before that, Mr. Storer held several positions with Baxter, most recently serving as Vice President of BioScience Finance where he provided financial leadership, internal controls and business partnership to the BioScience US commercial organization, global manufacturing, R&D, business development and all support functions. Mr. Storer began his work at Baxter as a financial analyst in 1997.